{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-24-000049","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.603812+00:00","generated_at":"2026-05-30T07:58:52.370148+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"United Therapeutics Q3 revenue $748.9M (+23% YoY); net income $309.1M (+16%)","bullets":["Total revenues $748.9M, +23% YoY; net income $309.1M ($6.39 diluted EPS) vs $267.6M ($5.38).","Tyvaso product revenues $433.8M, +33% YoY driven by Tyvaso DPI uptake and PH-ILD expansion.","Accrued $65.1M litigation liability related to ongoing Sandoz patent case; final judgment pending.","Completed $1B accelerated share repurchase; repurchased ~3.55M shares during Q2-Q3 2024.","Management notes record revenue sixth straight quarter; Tyvaso remains key growth driver."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-24-000049","json":"https://secwatch.observer/filing/0001082554-24-000049.json","markdown":"https://secwatch.observer/filing/0001082554-24-000049.md","text":"https://secwatch.observer/filing/0001082554-24-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255424000049/0001082554-24-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255424000049/uthr-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:58:52.370148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}